Abstract
The Tel2 (also known as Telo2) and Tti1 proteins control the cellular abundance of mammalian PIKKs and are integral components of mTORC1 and mTORC2. Here we report that Tel2 and Tti1 are targeted for degradation within mTORC1 by the SCFFbxo9 ubiquitin ligase to adjust mTOR signalling to growth factor availability. This process is primed by CK2, which translocates to the cytoplasm to mediate mTORC1-specific phosphorylation of Tel2/Tti1, subsequent to growth factor deprivation. As a consequence, mTORC1 is inactivated to restrain cell growth and protein translation whereas relief of feedback inhibition activates the PI(3)K/TORC2/Akt pathway to sustain survival. Significantly, primary human multiple myelomas exhibit high levels of Fbxo9. In this setting, PI(3)K/TORC2/Akt signalling and survival of multiple myeloma cells is dependent on Fbxo9 expression. Thus, mTORC1-specific degradation of the Tel2 and Tti1 proteins represents a central mTOR regulatory mechanism with implications in multiple myeloma, both in promoting survival and in providing targets for the specific treatment of multiple myeloma with high levels of Fbxo9 expression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jorgensen, P. & Tyers, M. How cells coordinate growth and division. Curr. Biol. 14, R1014–R1027 (2004).
Wullschleger, S., Loewith, R. & Hall, M. N. TOR signaling in growth and metabolism. Cell 124, 471–484 (2006).
Zoncu, R., Efeyan, A. & Sabatini, D. M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12, 21–35 (2011).
Mendoza, M. C., Er, E. E. & Blenis, J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 36, 320–328 (2011).
Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell 149, 274–293 (2012).
Takai, H., Wang, R. C., Takai, K. K., Yang, H. & de Lange, T. Tel2 regulates the stability of PI3K-related protein kinases. Cell 131, 1248–1259 (2007).
Hurov, K. E., Cotta-Ramusino, C. & Elledge, S. J. A genetic screen identifies the Triple T complex required for DNA damage signaling and ATM and ATR stability. Genes Dev. 24, 1939–1950 (2010).
Takai, H., Xie, Y., de Lange, T. & Pavletich, N. P. Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes. Genes Dev. 24, 2019–2030 (2010).
Horejsi, Z. et al. CK2 phospho-dependent binding of R2TP complex to TEL2 is essential for mTOR and SMG1 stability. Mol. Cell 39, 839–850 (2010).
Kaizuka, T. et al. Tti1 and Tel2 are critical factors in mammalian target of rapamycin complex assembly. J. Biol. Chem. 285, 20109–20116 (2010).
Hershko, A. & Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem. 67, 425–479 (1998).
Varshavsky, A. Three decades of studies to understand the functions of the ubiquitin family. Methods Mol. Biol. 832, 1–11 (2012).
Bassermann, F. & Pagano, M. Dissecting the role of ubiquitylation in the DNA damage response checkpoint in G2. Cell Death Differ. 17, 78–85 (2010).
Cardozo, T. & Pagano, M. The SCF ubiquitin ligase: insights into a molecular machine. Nat. Rev. Mol. Cell Biol. 5, 739–751 (2004).
Skaar, J. R., D’Angiolella, V., Pagan, J. K. & Pagano, M. SnapShot: F Box Proteins II. Cell 137, 1358 (2009).
Palumbo, A. & Anderson, K. Multiple myeloma. New Engl. J. Med. 364, 1046–1060 (2011).
Moreau, P. et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120, 947–959 (2012).
Rajkumar, S. V., Richardson, P. G., Hideshima, T. & Anderson, K. C. Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol. 23, 630–639 (2005).
Busino, L. et al. Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat. Cell Biol. 14, 375–385 (2012).
Bassermann, F. et al. The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint. Cell 134, 256–267 (2008).
Olsen, B. B., Guerra, B., Niefind, K. & Issinger, O. G. Structural basis of the constitutive activity of protein kinase CK2. Methods Enzymol. 484, 515–529 (2010).
Carrasco, D. R. et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9, 313–325 (2006).
Zhan, F. et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 109, 1692–1700 (2007).
Mattioli, M. et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 24, 2461–2473 (2005).
Peterson, T. R. et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137, 873–886 (2009).
Hsu, P. P. et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317–1322 (2011).
Yu, Y. et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322–1326 (2011).
Mulligan, G. et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 109, 3177–3188 (2007).
Rendtlew Danielsen, J. M. et al. HCLK2 is required for activity of the DNA damage response kinase ATR. J. Biol. Chem. 284, 4140–4147 (2009).
Trembley, J. H., Wang, G., Unger, G., Slaton, J. & Ahmed, K. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell. Mol. Life Sci.: CMLS 66, 1858–1867 (2009).
Litchfield, D. W. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem. J. 369, 1–15 (2003).
Battistutta, R. Protein kinase CK2 in health and disease: structural bases of protein kinase CK2 inhibition. Cell. Mol. Life Sci.: CMLS 66, 1868–1889 (2009).
Fernandez-Saiz, V. & Buchberger, A. Imbalances in p97 co-factor interactions in human proteinopathy. EMBO Rep. 11, 479–485 (2010).
Bassermann, F. et al. NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry. Cell 122, 45–57 (2005).
Dorrello, N. V. et al. S6K1- and βTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314, 467–471 (2006).
Bassermann, F. et al. Multisite phosphorylation of nuclear interaction partner of ALK (NIPA) at G2/M involves cyclin B1/Cdk1. J. Biol. Chem. 282, 15965–15972 (2007).
Stein, G. H. T98G: an anchorage-independent human tumor cell line that exhibits stationary phase G1 arrest in vitro. J. Cell Physiol. 99, 43–54 (1979).
Lisztwan, J. et al. Association of human CUL-1 and ubiquitin-conjugating enzyme CDC34 with the F-box protein p45(SKP2): evidence for evolutionary conservation in the subunit composition of the CDC34-SCF pathway. EMBO J. 17, 368–383 (1998).
Meredith, M. J. Rat hepatocytes prepared without collagenase: prolongedretention of differentiated characteristics in culture. Cell Biol. Toxicol. 4, 405–425 (1988).
Busino, L. et al. SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins. Science 316, 900–904 (2007).
Becker, K. F. et al. Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis. J. Pathol. 211, 370–378 (2007).
Wolff, C., Schott, C., Malinowsky, K., Berg, D. & Becker, K. F. Producing reverse phase protein microarrays from formalin-fixed tissues. Methods Mol. Biol. 785, 123–140 (2011).
Acknowledgements
We thank T. deLange, T. Dechow, J. Duyster, D. Guardavaccaro, R. Humar, N. Mizushima and M. Rudelius for reagents; K. Engel and C. Proud for suggestions; R. Faessler and D. Moik for help with the antibody production; A. L. Illert for help with the preparation of liver extracts; and K-F. Becker for help with the reverse-phase protein arrays. M.P. is an investigator with the Howard Hughes Medical Institute. This work was supported by grants from the German Research Foundation (Emmy Noether Program, BA 2851/3-1) and the German Cancer Aid (#109543) to F.B.
Author information
Authors and Affiliations
Contributions
V.F-S., B-S.T. and F.B. conceived and designed the research; V.F-S. and B-S.T. performed most of the experiments with crucial help from R.E., S.S., A-M.K. and J.K.; C.L. provided the 180 MM samples, and performed cytogenetic and Fbxo9 mRNA analyses; J.S-H. provided the MM bone marrow biopsies that were processed for reverse-phase protein microarray analyses by C.R.; L.B. performed analyses of gene expression data sets; S.L. and B.K. performed mass spectrometry; M.P. provided critical reagents; V.F.S, B-S.T., R.E., S.L., C.P., M.P., B.K. and F.B. analysed results; F.B. coordinated this work and wrote the manuscript with help from V.F-S. and B-S.T. All authors discussed the results and commented on the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Information
Supplementary Information (PDF 2373 kb)
Rights and permissions
About this article
Cite this article
Fernández-Sáiz, V., Targosz, BS., Lemeer, S. et al. SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma. Nat Cell Biol 15, 72–81 (2013). https://doi.org/10.1038/ncb2651
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncb2651
This article is cited by
-
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia
Journal of Hematology & Oncology (2023)
-
Endotoxin stabilizes protein arginine methyltransferase 4 (PRMT4) protein triggering death of lung epithelia
Cell Death & Disease (2021)
-
Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways
Journal of Hematology & Oncology (2017)
-
The mTOR Signaling Pathway in Myocardial Dysfunction in Type 2 Diabetes Mellitus
Current Diabetes Reports (2017)
-
Multiple across-strain and within-strain QTLs suggest highly complex genetic architecture for hypoxia tolerance in channel catfish
Molecular Genetics and Genomics (2017)